FI930195A7 - Biarylsubstituerade 4-aminosmoersyraamider - Google Patents

Biarylsubstituerade 4-aminosmoersyraamider Download PDF

Info

Publication number
FI930195A7
FI930195A7 FI930195A FI930195A FI930195A7 FI 930195 A7 FI930195 A7 FI 930195A7 FI 930195 A FI930195 A FI 930195A FI 930195 A FI930195 A FI 930195A FI 930195 A7 FI930195 A7 FI 930195A7
Authority
FI
Finland
Prior art keywords
biarylsubstituerade
aminosmoersyramide
Prior art date
Application number
FI930195A
Other languages
English (en)
Finnish (fi)
Other versions
FI930195A0 (fi
Inventor
Gary Ksander
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of FI930195A0 publication Critical patent/FI930195A0/fi
Publication of FI930195A7 publication Critical patent/FI930195A7/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI930195A 1992-01-22 1993-01-18 Biarylsubstituerade 4-aminosmoersyraamider FI930195A7 (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/824,132 US5217996A (en) 1992-01-22 1992-01-22 Biaryl substituted 4-amino-butyric acid amides

Publications (2)

Publication Number Publication Date
FI930195A0 FI930195A0 (fi) 1993-01-18
FI930195A7 true FI930195A7 (fi) 1993-07-23

Family

ID=25240671

Family Applications (1)

Application Number Title Priority Date Filing Date
FI930195A FI930195A7 (fi) 1992-01-22 1993-01-18 Biarylsubstituerade 4-aminosmoersyraamider

Country Status (14)

Country Link
US (2) US5217996A (https=)
EP (1) EP0555175A1 (https=)
JP (1) JPH05310664A (https=)
KR (1) KR930016393A (https=)
AU (1) AU666902B2 (https=)
CA (1) CA2087652A1 (https=)
FI (1) FI930195A7 (https=)
HU (1) HUT63376A (https=)
IL (1) IL104387A0 (https=)
MX (1) MX9300310A (https=)
NO (1) NO930193L (https=)
NZ (1) NZ245716A (https=)
TW (1) TW228513B (https=)
ZA (1) ZA93421B (https=)

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217996A (en) * 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
IL115995A0 (en) * 1994-11-15 1996-01-31 Bayer Ag Substituted 4-biarylbutyric or 5-biarylpentanoic acids and derivatives as matrix metalloprotease inhibitors
MX9706394A (es) * 1995-02-22 1997-11-29 Novartis Ag Compuestos de 1-aril-2-acilamino-etano y su uso como antagonistas de neuroquinina, especialmente neuroquinina-1.
MY132550A (en) 1996-08-22 2007-10-31 Novartis Ag Acylaminoalkenylene-amide derivatives as nk1 and nk2 antogonists
RU2245147C2 (ru) * 1999-03-29 2005-01-27 Бристол-Маерс Сквибб Компани Применение ингибитора вазопептидазы для лечения стенокардии
US7468390B2 (en) 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
NZ533968A (en) * 2002-01-17 2006-10-27 Novartis Ag Pharmaceutical compositions comprising valsartan and nep inhibitors
GB0203061D0 (en) * 2002-02-08 2002-03-27 Novartis Ag Organic compounds
ATE550656T1 (de) * 2003-08-20 2012-04-15 Alere San Diego Inc Verfahren und zusammensetzungen zur messung biologisch aktiver natriuretischer peptide und zur verbesserung ihres therapeutischen potentials
US7781478B2 (en) * 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
WO2006019831A1 (en) * 2004-07-14 2006-02-23 Ptc Therapeutics, Inc. Methods for treating hepatitis c
US7868037B2 (en) * 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) * 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
WO2006019832A1 (en) 2004-07-22 2006-02-23 Ptc Therapeutics, Inc. Thienopyridines for treating hepatitis c
MY146830A (en) * 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
WO2007045663A2 (en) * 2005-10-19 2007-04-26 Novartis Ag Combination of an ati receptor antagonist and a np inhibitor fro treating ia hypertension and heartfailure
AR057882A1 (es) * 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
RU2459809C2 (ru) * 2005-11-09 2012-08-27 Новартис Аг Фармацевтические комбинации антагониста рецептора ангиотензина и ингибитора nep
EP1903027A1 (en) * 2006-09-13 2008-03-26 Novartis AG Process for preparing biaryl substituted 4-amino-butyric acid or derivatives thereof and their use in the production of NEP inhibitors
PH12012502091A1 (en) * 2007-01-12 2019-06-14 Novartis Ag Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid
TW200838501A (en) * 2007-02-02 2008-10-01 Theravance Inc Dual-acting antihypertensive agents
TWI448284B (zh) 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
TWI406850B (zh) 2007-06-05 2013-09-01 Theravance Inc 雙效苯并咪唑抗高血壓劑
WO2009035543A1 (en) 2007-09-07 2009-03-19 Theravance, Inc. Dual-acting antihypertensive agents
EP2209786B1 (en) * 2007-10-05 2013-02-27 Verastem, Inc. Pyrimidine substituted purine derivatives
JP2011506459A (ja) * 2007-12-11 2011-03-03 セラヴァンス， インコーポレーテッド 抗高血圧剤としての二重作用性ベンゾイミダゾール誘導体およびその使用
AR070176A1 (es) * 2008-01-17 2010-03-17 Novartis Ag Procesos de sintesis de inhibidores de nep, compuestos intermediarios y uso de los mismos en la sintesis
AU2012202949B2 (en) * 2008-01-17 2015-01-22 Novartis Ag Process and intermediates for the preparation of 5-biphenyl-4-yl-2-methylpentanoic acid derivatives
EP2297113A1 (en) 2008-04-29 2011-03-23 Theravance, Inc. Dual-acting antihypertensive agents
CN101607875B (zh) * 2008-06-17 2012-07-25 中国石油化学工业开发股份有限公司 制造环烷酮的方法
JP2011529072A (ja) 2008-07-24 2011-12-01 セラヴァンス， インコーポレーテッド 二重作用血圧降下薬
CN101774941A (zh) * 2009-01-13 2010-07-14 浙江九洲药业股份有限公司 2-酰基氨基-3-联苯基丙酸的制备及拆分方法
JP2012526810A (ja) 2009-05-13 2012-11-01 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
SG176009A1 (en) * 2009-05-28 2011-12-29 Novartis Ag Substituted aminopropionic derivatives as neprilysin inhibitors
JP5466759B2 (ja) 2009-05-28 2014-04-09 ノバルティス アーゲー ネプリライシン阻害剤としての置換アミノ酪酸誘導体
WO2011005674A1 (en) 2009-07-07 2011-01-13 Theravance, Inc. Dual-acting pyrazole antihypertensive agents
JP2012533626A (ja) 2009-07-22 2012-12-27 セラヴァンス， インコーポレーテッド 二重作用オキサゾール降圧剤
JO2967B1 (en) * 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
EP2526095A1 (en) 2010-01-19 2012-11-28 Theravance, Inc. Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents
AU2011207020B2 (en) 2010-01-22 2014-04-17 Novartis Ag Intermediates of neutral endopeptidase inhibitors and preparation method thereof
MX2013002149A (es) * 2010-08-23 2013-04-03 Novartis Ag Nuevo proceso para la preparacion de intermediarios utiles para la elaboracion de inhibidores de nep.
BR112013004164A2 (pt) 2010-08-23 2016-05-10 Novartis Ag processo para a preparação de intermediários para a produção de inibidores da nep
AU2011293648B2 (en) 2010-08-24 2015-02-12 Novartis Ag Treatment of hypertension and/or prevention or treatment of heart failure in a mammal receiving anti-coagulant therapy
US8673974B2 (en) * 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8993631B2 (en) 2010-11-16 2015-03-31 Novartis Ag Method of treating contrast-induced nephropathy
HUE028051T2 (hu) * 2010-12-15 2016-11-28 Theravance Biopharma R&D Ip Llc Neprilizin inhibitorok
CA2819153A1 (en) 2010-12-15 2012-06-21 Theravance, Inc. Neprilysin inhibitors
JP5959066B2 (ja) 2011-02-17 2016-08-02 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ネプリライシン阻害剤としての置換アミノ酪酸誘導体
JP5959065B2 (ja) * 2011-02-17 2016-08-02 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ネプリライシン阻害剤としての置換アミノ酪酸誘導体
JP5959074B2 (ja) 2011-05-31 2016-08-02 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ネプリライシン阻害剤
CN103748070B (zh) 2011-05-31 2015-06-24 施万生物制药研发Ip有限责任公司 脑啡肽酶抑制剂
CN103582630B (zh) 2011-05-31 2016-08-17 施万生物制药研发Ip有限责任公司 脑啡肽酶抑制剂
TWI560172B (en) 2011-11-02 2016-12-01 Theravance Biopharma R&D Ip Llc Neprilysin inhibitors
TWI562986B (en) * 2012-02-15 2016-12-21 Theravance Biopharma R&D Ip Llc Process for preparing 4-amino-5-biphenyl-4-yl-2-hydroxymethyl-2-methyl-pentanoic acid compounds
CA2871292A1 (en) 2012-05-31 2013-12-05 Theravance Biopharma R&D Ip, Llc Nitric oxide donor neprilysin inhibitors
WO2013184898A1 (en) 2012-06-08 2013-12-12 Theravance, Inc. Neprilysin inhibitors
SMT201700306T1 (it) 2012-06-08 2017-07-18 Theravance Biopharma R&D Ip Llc Inibitori di neprilisina
MX366149B (es) 2012-08-08 2019-06-28 Theravance Biopharma R&D Ip Llc Inhibidores de neprilisina.
AU2013304949C1 (en) * 2012-08-24 2020-12-24 Novartis Ag NEP inhibitors for treating diseases characterized by atrial enlargement or remodeling
TR201808541T4 (tr) 2013-02-14 2018-07-23 Novartis Ag Nep (nötr endopeptidaz) inhibitörleri olarak ikame edilmiş bisfenil butanoik fosfonik asit türevleri.
JP6301371B2 (ja) 2013-02-14 2018-04-11 ノバルティス アーゲー インビボ効力が改善されたｎｅｐ阻害剤としての置換ビスフェニルブタン酸誘導体
US9801882B2 (en) 2013-02-17 2017-10-31 Intra-Cellular Therapies, Inc. Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases
DK2964616T3 (en) 2013-03-05 2017-08-28 Theravance Biopharma R&D Ip Llc Neprilysin inhibitors
CN104230865B (zh) * 2013-06-13 2018-01-09 上海翰森生物医药科技有限公司 联芳基取代的4‑氨基丁酸衍生物及其制备方法和用途
EP3038653A1 (en) 2013-08-26 2016-07-06 Novartis AG New use
ES2968541T3 (es) 2013-08-26 2024-05-10 Novartis Ag Tratamiento de enfermedades cardiovasculares
CA2934898A1 (en) 2014-01-30 2015-08-06 Theravance Biopharma R&D Ip, Llc 5-biphenyl-4-heteroarylcarbonylamino-pentanoic acid derivatives as neprilysin inhibitors
CA2934936A1 (en) 2014-01-30 2015-08-06 Theravance Biopharma R&D Ip, Llc Neprilysin inhibitors
WO2015154673A1 (en) * 2014-04-10 2015-10-15 Zhaoyin Wang Novel prodrugs and combinations for treatment of hypertension and cardiovascular diseases
US10131671B2 (en) 2014-08-07 2018-11-20 Intra-Cellular Therapies, Inc. Organic compounds
CN106458857A (zh) * 2014-08-27 2017-02-22 上海翰森生物医药科技有限公司 AHU‑377结晶型游离酸、半钙盐、α﹣苯乙胺盐及其制备方法和应用
CN105461587A (zh) * 2014-08-27 2016-04-06 上海翰森生物医药科技有限公司 Ahu-377半钙盐晶型及其制备方法和应用
CN105622452A (zh) * 2014-08-27 2016-06-01 上海翰森生物医药科技有限公司 Ahu-377结晶型游离酸及其制备方法和应用
CN105367438A (zh) * 2014-08-27 2016-03-02 上海翰森生物医药科技有限公司 AHU-377α-苯乙胺盐多晶型及其制备方法和应用
WO2016037098A1 (en) 2014-09-04 2016-03-10 Concert Pharmaceuticals, Inc. Deuterated sacubitril
LT3218351T (lt) 2014-11-14 2019-09-25 Zentiva K.S. Ahu-377 farmaciniu požiūriu priimtinų formų gavimo, atskyrimo ir gryninimo būdas
CN105693543B (zh) * 2014-12-15 2018-08-10 四川海思科制药有限公司 沙库比曲类衍生物、其药物组合物、制备方法及用途
CN104557600B (zh) * 2015-01-26 2016-05-04 苏州明锐医药科技有限公司 沙库比曲的制备方法
JP6766055B2 (ja) 2015-02-11 2020-10-07 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ネプリライシン阻害剤としての（２ｓ，４ｒ）−５−（５’−クロロ−２’−フルオロビフェニル−４−イル）−４−（エトキシオキサリルアミノ）−２−ヒドロキシメチル−２−メチルペンタン酸
TW201632493A (zh) 2015-02-13 2016-09-16 諾華公司 新穎方法
LT3259255T (lt) 2015-02-19 2021-04-26 Theravance Biopharma R&D Ip, Llc (2r,4r)-5-(5`-chlor-2`-fluorbifenil-4-il)-2-hidroksi-4-[(5-metiloksazol-2-karbonil)amino]pentano rūgštis
WO2016135751A1 (en) 2015-02-25 2016-09-01 Mylan Laboratories Limited Novel process for the preparation of sacubitril and its intermediates
CN105963296B (zh) * 2015-03-12 2020-01-21 深圳信立泰药业股份有限公司 一种含有阿利沙坦酯或其盐或其水解产物或其水解产物盐的药物组合物及其用途
WO2016150337A1 (zh) * 2015-03-20 2016-09-29 苏州晶云药物科技有限公司 Ahu377的晶型及其制备方法与用途
EP4570314A3 (en) 2015-05-11 2025-09-10 Novartis AG Sacubitril-valsartan dosage regimen for treating chronic systolic heart failure
WO2016193883A1 (en) 2015-05-29 2016-12-08 Novartis Ag Sacubitril and valsartan for treating metabolic disease
CN104860894B (zh) * 2015-06-10 2017-05-17 北京博全健医药科技有限公司 一种抗心衰药lcz696的制备方法
WO2016201238A1 (en) 2015-06-12 2016-12-15 Teva Pharmaceuticals International Gmbh Solid state forms of trisodium valsartan: sacubitril
WO2016203500A2 (en) 2015-06-19 2016-12-22 Actavis Group Ptc Ehf. Preparation of sacubitril or salt thereof and novel intermediates in the preparation of sacubitril
SI3317248T1 (sl) * 2015-07-02 2021-01-29 Novartis Ag Sakubitril kalcijeve soli
WO2017006254A1 (en) 2015-07-08 2017-01-12 Novartis Ag Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist
WO2017009784A1 (en) 2015-07-14 2017-01-19 Cadila Healthcare Limited Solid state forms of trisodium salt of valsartan/sacubitril complex and sacubitril
WO2017012600A1 (en) 2015-07-20 2017-01-26 Zentiva, K.S. A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof
JP6849618B2 (ja) 2015-07-23 2021-03-24 バイエル・ファルマ・アクティエンゲゼルシャフト 中性エンドペプチダーゼの阻害剤（ＮＥＰ阻害剤）および／またはアンジオテンシンＩＩ拮抗薬と組み合わせた可溶性グアニル酸シクラーゼ（ｓＧＣ）の刺激薬および／または活性化薬ならびにその使用
WO2017029261A1 (de) * 2015-08-19 2017-02-23 Bayer Pharma Aktiengesellschaft Kombinationspräparat umfassend finerenone und einen nep-inhibitor (sacubitril)
WO2017033128A1 (en) 2015-08-25 2017-03-02 Novartis Ag Biphenyl-substitued 4-amino-butyric acid derivatives and their use in the synthesis of nep inhibitors
WO2017037577A1 (en) 2015-08-28 2017-03-09 Novartis Ag New use
WO2017051326A1 (en) 2015-09-23 2017-03-30 Novartis Ag New processes and intermediates useful in synthesis of nep inhibitors
US20180311241A1 (en) 2015-10-29 2018-11-01 Cadila Healthcare Limited Pharmaceutical synergistic combination
US10377697B2 (en) 2015-12-10 2019-08-13 Novartis Ag Process and intermediates
EP3386945A1 (en) * 2015-12-11 2018-10-17 Zentiva, K.S. Solid forms of (2r,4s)-5-(biphenyl-4-yl)-4-[(3-carboxypropionyl)amino]-2- -methylpentanoic acid ethyl ester, its salts and a preparation method
CN106977417A (zh) * 2016-01-15 2017-07-25 常州方楠医药技术有限公司 一种沙库比曲钠盐的晶型及其制备方法
JP7156945B2 (ja) 2016-02-03 2022-10-19 ノバルティス アーゲー 有機化合物のガレヌス製剤
JP7306828B2 (ja) 2016-03-08 2023-07-11 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー 結晶性（２ｓ，４ｒ）－５－（５’－クロロ－２’－フルオロ－［１，１’－ビフェニル］－４－イル）－２－（エトキシメチル）－４－（３－ヒドロキシイソオキサゾール－５－カルボキサミド）－２－メチルペンタン酸およびその使用
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
CN105753733B (zh) * 2016-04-15 2019-06-18 苏州晶云药物科技股份有限公司 Ahu377的晶型及其制备方法与用途
CN105820064A (zh) * 2016-04-18 2016-08-03 浙江天宇药业股份有限公司 一种联苯基丙氨醇衍生物的合成方法及中间体
WO2017191620A1 (en) * 2016-05-06 2017-11-09 Sun Pharmaceutical Industries Limited A crystalline form of a salt of sacubitril and a process of its preparation
US20190256454A1 (en) 2016-07-05 2019-08-22 Novartis Ag New process for early sacubitril intermediates
CN107602399B (zh) * 2016-07-11 2020-09-25 江西东邦药业有限公司 一种脑啡肽酶抑制剂中间体的制备方法
CN109563019A (zh) 2016-08-17 2019-04-02 诺华股份有限公司 Nep抑制剂合成的新方法和中间体
CN106318988B (zh) * 2016-08-23 2020-11-03 迪嘉药业集团有限公司 一种lcz696关键中间体的制备方法
WO2018045505A1 (zh) 2016-09-07 2018-03-15 诺瑞特国际药业股份有限公司 沙库比曲钠盐新晶型
CN106478437A (zh) * 2016-09-27 2017-03-08 南通常佑药业科技有限公司 一种γ‑氨基戊酸酯衍生物的制备方法
CN106496055A (zh) * 2016-10-09 2017-03-15 杭州科巢生物科技有限公司 一种抗心衰新药的关键组分沙库比曲的新合成方法
WO2018069833A1 (en) 2016-10-10 2018-04-19 Laurus Labs Limited Stable amorphous form of sacubitril valsartan trisodium complex and processes for preparation thereof
RU2019115782A (ru) 2016-10-28 2020-11-30 Биокон Лимитед Аморфный тринатрий сакубитрил вальсартан и способ его получения
US10774036B2 (en) 2016-12-23 2020-09-15 Novartis Ag Process for early sacubitril intermediates
WO2018153895A1 (de) 2017-02-22 2018-08-30 Bayer Pharma Aktiengesellschaft Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit einem inhibitor der neutralen endopeptidase und/oder einem angiotensin ii rezeptor-antagonisten
CN106831473B (zh) * 2017-02-22 2019-07-16 江西瑞雅药业有限公司 3-酰胺基-4-(2’-烷氧基-4-联苯基)丁酸衍生物及其制备方法、药物组合物
WO2018178295A1 (en) 2017-03-31 2018-10-04 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Stable hot-melt extrudate containing valsartan and sacubitril
WO2019020706A1 (en) 2017-07-28 2019-01-31 Synthon B.V. PHARMACEUTICAL COMPOSITION COMPRISING SACUBITRIL AND VALSARTAN
US20200276129A1 (en) 2017-10-13 2020-09-03 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Tablet containing valsartan and sacubitril
CN108530371B (zh) * 2017-12-27 2020-09-01 浙江天宇药业股份有限公司 一种沙库比曲钠盐、沙库比曲游离酸与乙酸的共晶物、其晶型、晶型的制备方法及用途
JP7401442B2 (ja) 2018-01-31 2023-12-19 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規使用
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
GB201810326D0 (en) * 2018-06-22 2018-08-08 Johnson Matthey Plc Crystalline form of sacubitril, its preparation and use
WO2020039386A1 (en) 2018-08-23 2020-02-27 Novartis Ag New pharmaceutical use for the treatment of heart failure
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
CN109503404A (zh) * 2018-12-28 2019-03-22 凯瑞斯德生化(苏州)有限公司 一种lcz-696关键中间体的制备方法
CN110128298B (zh) * 2019-06-13 2021-08-03 南京一心和医药科技有限公司 一种沙库巴曲中间体的合成方法
CN113135836A (zh) * 2020-01-20 2021-07-20 鲁南制药集团股份有限公司 一种沙库巴曲钙盐的制备方法
CN111253425B (zh) * 2020-02-21 2022-04-29 常州南京大学高新技术研究院 一种1,3-双[2-(3,4-环氧环己基)乙基]四甲基二硅氧烷的合成方法
JP7064527B2 (ja) * 2020-05-01 2022-05-10 ノバルティス アーゲー サクビトリルカルシウム塩
KR20220012821A (ko) 2020-07-23 2022-02-04 주식회사 종근당 이중 작용 복합 화합물의 결정형 및 이의 제조방법
CN112661671B (zh) * 2020-12-22 2022-04-22 江苏阿尔法药业股份有限公司 一种沙库巴曲中间体的制备方法
WO2022224274A1 (en) 2021-04-20 2022-10-27 Mylan Laboratories Limited Polymorphic forms of sacubitril-telmisartan (1:1)
CN117645555A (zh) * 2023-11-30 2024-03-05 南京欧信医药技术有限公司 一种利用连续流管式反应器合成沙库巴曲中间体的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE250531C (https=) *
US2543267A (en) * 1950-01-04 1951-02-27 Parke Davis & Co Hydroxyethyl-acylamidobiphenylyl ketones
US4206232A (en) * 1976-05-10 1980-06-03 E. R. Squibb & Sons, Inc. Relieving hypertension with carboxyalkylacylamino acids
FR2480747A1 (fr) * 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
US4721726A (en) * 1980-12-18 1988-01-26 Schering Corporation Substituted dipeptides as inhibitors of enkephalinases
US4939261A (en) * 1984-06-08 1990-07-03 Ciba-Geigy Corporation N-substituted butyramide derivatives useful for treatment of conditions responsive to inhibition of enkephalinase
US5096925A (en) * 1984-06-08 1992-03-17 Ciba-Geigy Corporation N-substituted butyramide derivatives
EP0225292A3 (en) * 1985-12-06 1988-11-30 Ciba-Geigy Ag Certain n-substituted butyramide derivatives
DD250531A1 (de) * 1985-12-23 1987-10-14 Adw Ddr Verfahren zur herstellung von malonylaminosaeure-p-nitrobenzylestern
CA1337400C (en) * 1987-06-08 1995-10-24 Norma G. Delaney Inhibitors of neutral endopeptidase
US5169976A (en) * 1987-11-25 1992-12-08 Pfizer Inc. N-(biphenylmethyl)-3-hydroxyglutaramic acid and derivatives as hypocholesterolemic agents
WO1991005555A2 (en) * 1989-10-13 1991-05-02 The Salk Institute Biotechnology/Industrial Associates, Inc. N-acyl peptide metalloendopeptidase inhibitors and methods of using same
US5217996A (en) * 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides

Also Published As

Publication number Publication date
NZ245716A (en) 1995-07-26
NO930193D0 (no) 1993-01-21
NO930193L (no) 1993-07-23
AU666902B2 (en) 1996-02-29
HU9300166D0 (en) 1993-04-28
CA2087652A1 (en) 1993-07-23
US5354892A (en) 1994-10-11
MX9300310A (es) 1993-07-01
KR930016393A (ko) 1993-08-26
IL104387A0 (en) 1993-05-13
TW228513B (https=) 1994-08-21
EP0555175A1 (en) 1993-08-11
AU3184293A (en) 1993-07-29
FI930195A0 (fi) 1993-01-18
ZA93421B (en) 1993-07-22
US5217996A (en) 1993-06-08
HUT63376A (en) 1993-08-30
JPH05310664A (ja) 1993-11-22

Similar Documents

Publication Publication Date Title
DK1127807T3 (da) Pose-i-karton
FI930195A7 (fi) Biarylsubstituerade 4-aminosmoersyraamider
NO933953L (no) Kjökkenventilator
DE59306810D1 (de) Gutbettwalzenmühle
FI931536A0 (fi) Antikontamineringsbehandling foer papperstillverkningsvaevnader
NO930053D0 (no) Permanentvaeske
AT399443B (de) Sportschuh
BR9305745A (pt) Quebra-luz
DE59305364D1 (de) Rotornut
DE69304512D1 (de) Laseroszillator
DE69306208D1 (de) Ablenkjoch
FI931056L (fi) Lineaert viskoelastisk flytande vattenhaltig tvaettmedelsammansaettning foer automatisk diskmaskin
BR9301712A (pt) Aplainador
IT229129Y1 (it) Girella cogliolive
ATA227792A (de) Sportschuh
DE59309200D1 (de) Bisphosphinoalkane
FI574U1 (fi) Baottvaettmaskin
FI400U1 (fi) Foerbindelsesteg
FI706U1 (fi) Lyftanordning foer motorkaelke
BR9200296A (pt) Varre-lava
BR7201859U (pt) Cambao
FIU920180U0 (fi) Vindkraftverk
FIU920497U0 (fi) Massageapparat
BR7200318U (pt) Cabide sanfonado
FIU920578U0 (fi) Anordning foer kraftuttag

Legal Events

Date Code Title Description
FD Application lapsed